DICE: Customer relationships that proved strategic value and drove an exit

DICE built a clear commercialization pathway: discover oral small molecules that recapitulate biologic targets, then monetize through research collaborations, exclusive licensing options, milestone and option fees, and strategic exit. For investors and operators assessing customer-counterparty risk, the DICE record reads as a classic small-biotech playbook — early scientific validation from large pharma partners, concentrated counterparties with exclusive option mechanics, and ultimate value realization through acquisition. Explore the relationships below to understand where value was created and how counterparties influenced commercial optionality. For deeper coverage of counterparty footprints and contracting signals visit https://nullexposure.com/.

How the partner roster shaped commercial optionality

DICE’s commercial model emphasized partnerships over broad commercialization: discovery services and option-to-license structures created discrete value events (option exercises, milestones) rather than recurring product revenues. That contracting posture concentrates downside and upside into a small number of binary outcomes — option exercises and asset buyouts — which increases both leverage and execution risk for investors. The partner list is compact and heavyweight, which signals high validation but concentration risk: a handful of large pharma relationships were sufficient to de-risk programs scientifically and to attract a strategic acquirer. Learn more about counterparty concentration and disclosure practices at https://nullexposure.com/.

Genentech — a research-services relationship with limited take-up through 2020

Genentech contracted research services with DICE, but as of the end of 2020 had not requested additional research services nor exercised customer options available under the contract, indicating limited commercial engagement under that agreement at that point. This relationship provided scientific validation but did not translate into exercised licensing at least through FY2020. (MedCity News, 2021: https://medcitynews.com/2021/09/dices-ipo-roll-comes-up-with-204m-for-rd-of-oral-drugs-to-rival-biologics/)

Sanofi — an exclusive option partnership in immuno-oncology

DICE entered an immuno-oncology research partnership with Sanofi in 2015 that granted Sanofi an exclusive option to license, develop, and commercialize compounds discovered by DICE, establishing a classic pharma–biotech option pathway for value capture. The structure created a pathway for option fees and downstream milestones if Sanofi exercised rights on discovered compounds. (MedCity News, 2021: https://medcitynews.com/2021/09/dices-ipo-roll-comes-up-with-204m-for-rd-of-oral-drugs-to-rival-biologics/)

Lilly — the strategic acquirer that delivered exit liquidity

In FY2024, Eli Lilly executed a definitive strategic outcome when it acquired DICE for $2.4 billion, purchasing the company and its platform for discovering oral small molecules that target the same biology as injected biologics. The acquisition converts prior option-driven optionality into realized value for shareholders and represents the ultimate monetization path for DICE’s partnership-led model. (MedCity News, 2024: https://medcitynews.com/2024/07/eli-lilly-acquisition-morphic-immunology-inflammation-inflammatory-bowel-ibd-lly/)

What these relationships mean for counterparty risk and value capture

• Concentrated counterparties: DICE worked with a small set of large pharmas — Genentech and Sanofi — and ultimately with Lilly through acquisition. That concentration produced high signal (validation) but high counterparty dependence; a few commercial decisions by partners governed major value inflection points.
• Option-heavy contracting posture: The dominance of exclusive options and research-service arrangements reveals a commercial model that prioritized milestone-capital events over recurring revenue, creating binary investment outcomes that either deliver substantial upside or leave assets under-commercialized.
• Strategic criticality: For partners, the value was platform- and asset-specific; for DICE, partner endorsements acted as credibility multipliers, culminating in an acquisition that converted strategic interest into enterprise value.
• Maturity pathway: DICE operated as a clinical-stage innovator whose partner relationships were oriented toward discovery and early-stage development, with eventual monetization via acquisition rather than internal commercialization.

These characteristics create a repeatable investor playbook: seek validation from blue-chip partners but price in concentration and option execution risk.

Company-level constraints and disclosure signals

No contractual constraints were included in the provided materials for this customer-scope review — this absence itself is a company-level signal. A lack of captured constraints suggests either minimal public disclosure for the contract elements covered here or that the material contracting levers were captured in filing narratives and press coverage rather than constraint excerpts. For investors, this indicates the need to review primary filing language and partner agreements to confirm payment schedules, option timelines, and exclusivity scopes.

Risk and opportunity — what to watch if you’re evaluating similar models

• Upside concentration: A small number of large counterparties can drive significant upside (as with Lilly’s acquisition) but also concentrate execution risk if options are not exercised.
• Timing risk on options: Option-driven monetization compresses the decision-making horizon into discrete events; investors must monitor option exercise windows and preclinical/clinical readouts closely.
• Validation vs. commercialization: Partnerships with top-tier pharma provide strong validation but do not guarantee downstream commercialization unless option exercises and licensing milestones are triggered.

For a portfolio-level assessment, prioritize clarity on option economics, milestone triggers, and any retained rights that affect post-license value capture.

Final takeaways and next steps

• DICE’s partner roster delivered the mix of scientific validation and strategic optionality that led to a $2.4 billion acquisition by Eli Lilly.
• The company’s contracting posture favored exclusive options and research services, which creates concentrated counterparty risk even as it accelerates strategic exits.
• For investors evaluating similar opportunities, focus diligence on option mechanics, counterparties’ historical exercise behavior, and the timeline alignment between discovery programs and partner development priorities.

Explore deeper counterparty analytics and deal-structure templates to operationalize these lessons at https://nullexposure.com/. If you want tailored counterparty risk scoring for a biotech portfolio or deal diligence support, start with the resources at https://nullexposure.com/ — our coverage maps partner footprints and contracting patterns to asset-level outcomes.